Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Allogene Therapeutics, Inc. (ALLO)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
  Older >>
In millions, except per share itemsJun-30-23Jun-30-22Mar-31-22Dec-31-21Sep-30-21Jun-30-21Mar-31-21Dec-31-20
   10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K
Revenues   0.20.238.538.438.438.30.0
            Revenue growth   -99.4%-99.5%     
Cost of goods sold   0.00.00.00.00.00.00.0
Gross profit   0.20.238.538.438.438.30.0
            Gross margin   100.0%100.0%100.0%100.0%100.0%100.0% 
Selling, general and administrative   [+] 78.477.674.171.368.966.065.3
Research and development   230.0225.1220.2218.4211.1206.1193.0
EBITDA   [+] -294.2-290.4-245.3-243.2-234.1-226.3-250.7
            EBITDA margin   -119113.4%-141637.1%-637.4%-632.7%-609.8%-590.2% 
Depreciation and amortization   13.912.210.58.17.57.57.4
EBIT   [+] -308.1-302.6-255.8-251.3-241.6-233.8-258.2
            EBIT margin   -124756.7%-147602.0%-664.6%-653.7%-629.4%-609.6% 
Interest income   2.0 2.3 9.8 9.2
Other income (expense), net   -1.6-3.6-3.5-9.2-6.9-4.2-1.1
Pre-tax income   -307.7-303.8-257.0-250.7-238.7-228.8-250.2
Income taxes   0.00.00.00.00.00.00.0
            Tax rate   0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income   -307.7-303.8-257.0-250.7-238.7-228.8-250.2
            Net margin   -124571.3%-148214.6%-667.7%-652.2%-621.8%-596.6% 
   
Basic EPS   [+] ($2.21)($2.21)($1.90)($1.91)($1.86)($1.85)($2.12)
Diluted EPS   [+] ($2.21)($2.21)($1.90)($1.91)($1.86)($1.85)($2.12)
   
Shares outstanding (basic)   [+] 139.4137.3135.0131.1128.6123.8118.0
Shares outstanding (diluted)   [+] 139.4137.3135.0131.1128.6123.8118.0
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy